181 related articles for article (PubMed ID: 31591015)
21. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
Montanari R; Saccoccia F; Scotti E; Crestani M; Godio C; Gilardi F; Loiodice F; Fracchiolla G; Laghezza A; Tortorella P; Lavecchia A; Novellino E; Mazza F; Aschi M; Pochetti G
J Med Chem; 2008 Dec; 51(24):7768-76. PubMed ID: 19053776
[TBL] [Abstract][Full Text] [Related]
22. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
[TBL] [Abstract][Full Text] [Related]
23. Galangin 3-benzyl-5-methylether derivatives function as an adiponectin synthesis-promoting peroxisome proliferator-activated receptor γ partial agonist.
Ko H; Jang H; An S; Park IG; Ahn S; Gong J; Hwang SY; Oh S; Kwak SY; Choi WJ; Kim H; Noh M
Bioorg Med Chem; 2022 Jan; 54():116564. PubMed ID: 34922307
[TBL] [Abstract][Full Text] [Related]
24. Synthesis of docosahexaenoic acid derivatives designed as novel PPARgamma agonists and antidiabetic agents.
Itoh T; Murota I; Yoshikai K; Yamada S; Yamamoto K
Bioorg Med Chem; 2006 Jan; 14(1):98-108. PubMed ID: 16198578
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents.
Li Z; Hu L; Wang X; Zhou Z; Deng L; Xu Y; Zhang L
Bioorg Chem; 2019 Nov; 92():103254. PubMed ID: 31518760
[TBL] [Abstract][Full Text] [Related]
26. Design, Synthesis, and Structure-Activity Relationships of Bavachinin Analogues as Peroxisome Proliferator-Activated Receptor γ Agonists.
Du G; Zhao Y; Feng L; Yang Z; Shi J; Huang C; Li B; Guo F; Zhu W; Li Y
ChemMedChem; 2017 Jan; 12(2):183-193. PubMed ID: 27914122
[TBL] [Abstract][Full Text] [Related]
27. Structural basis for the improved potency of peroxisome proliferator-activated receptor (PPAR) agonists.
Peng YH; Coumar MS; Leou JS; Wu JS; Shiao HY; Lin CH; Lin WH; Lien TW; Chen X; Hsu JT; Chao YS; Huang CF; Lyu PC; Hsieh HP; Wu SY
ChemMedChem; 2010 Oct; 5(10):1707-16. PubMed ID: 20734309
[TBL] [Abstract][Full Text] [Related]
28. Structure-Activity Relationship of 2,4-Dichloro-N-(3,5-dichloro-4-(quinolin-3-yloxy)phenyl)benzenesulfonamide (INT131) Analogs for PPARγ-Targeted Antidiabetics.
Frkic RL; He Y; Rodriguez BB; Chang MR; Kuruvilla D; Ciesla A; Abell AD; Kamenecka TM; Griffin PR; Bruning JB
J Med Chem; 2017 Jun; 60(11):4584-4593. PubMed ID: 28485590
[TBL] [Abstract][Full Text] [Related]
29. Discovery of novel indazole derivatives as dual angiotensin II antagonists and partial PPARγ agonists.
Lamotte Y; Faucher N; Sançon J; Pineau O; Sautet S; Fouchet MH; Beneton V; Tousaint JJ; Saintillan Y; Ancellin N; Nicodeme E; Grillot D; Martres P
Bioorg Med Chem Lett; 2014 Feb; 24(4):1098-103. PubMed ID: 24462665
[TBL] [Abstract][Full Text] [Related]
30. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro.
Burgermeister E; Schnoebelen A; Flament A; Benz J; Stihle M; Gsell B; Rufer A; Ruf A; Kuhn B; Märki HP; Mizrahi J; Sebokova E; Niesor E; Meyer M
Mol Endocrinol; 2006 Apr; 20(4):809-30. PubMed ID: 16373399
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and bioactivity evaluation of thiazolidinedione derivatives as partial agonists targeting PPARγ.
Sun J; Liu HY; Zhang YH; Fang ZY; Lv PC
Bioorg Chem; 2021 Nov; 116():105342. PubMed ID: 34536928
[TBL] [Abstract][Full Text] [Related]
32. Synthesis of N-(5-chloro-6-(quinolin-3-yloxy)pyridin-3-yl)benzenesulfonamide derivatives as non-TZD peroxisome proliferator-activated receptor γ (PPARγ) agonist.
Bajare S; Anthony J; Nair A; Marita R; Damre A; Patel D; Rao C; Sivaramakrishnan H; Deka N
Eur J Med Chem; 2012 Dec; 58():355-60. PubMed ID: 23142675
[TBL] [Abstract][Full Text] [Related]
33. Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis.
Liu C; Feng T; Zhu N; Liu P; Han X; Chen M; Wang X; Li N; Li Y; Xu Y; Si S
Sci Rep; 2015 Apr; 5():9530. PubMed ID: 25827822
[TBL] [Abstract][Full Text] [Related]
34. Discovery of BR102375, a new class of non-TZD PPARγ full agonist for the treatment of type 2 diabetes.
Choung W; Yang D; Kim H; Choi H; Lee BR; Park M; Jang SM; Lim JS; Kim WS; Kim KH; Chin J; Jung K; Lee G; Hong E; Jang TH; Joo J; Hwang H; Myung J; Kim SH
Bioorg Med Chem Lett; 2019 Aug; 29(16):2275-2282. PubMed ID: 31253533
[TBL] [Abstract][Full Text] [Related]
35. [Design, synthesis, and PPARalpha/gamma agonistic activity of novel tetrahydroisoquinoline derivatives].
Yu R; Zhou YL; Huan Y; Liu Q; Shen ZF; Liu ZZ
Yao Xue Xue Bao; 2011 Mar; 46(3):311-6. PubMed ID: 21626786
[TBL] [Abstract][Full Text] [Related]
36. [Design, synthesis and antidiabetic activity of novel tetrahydrocarboline PPAR regulators].
Peng K; Huan Y; Liu Q; Shen ZF; Liu ZZ
Yao Xue Xue Bao; 2014 Apr; 49(4):490-6. PubMed ID: 24974466
[TBL] [Abstract][Full Text] [Related]
37. Development of docking-based 3D-QSAR models for PPARgamma full agonists.
Guasch L; Sala E; Valls C; Mulero M; Pujadas G; Garcia-Vallvé S
J Mol Graph Model; 2012 Jun; 36():1-9. PubMed ID: 22503857
[TBL] [Abstract][Full Text] [Related]
38. Design and synthesis of benzoxazole containing indole analogs as peroxisome proliferator-activated receptor-γ/δ dual agonists.
Gim HJ; Cheon YJ; Ryu JH; Jeon R
Bioorg Med Chem Lett; 2011 May; 21(10):3057-61. PubMed ID: 21482466
[TBL] [Abstract][Full Text] [Related]
39. Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
Henry JR; Li Y; Warshawsky AM; Brozinick JT; Hawkins ED; Misener EA; Briere DA; Montrose-Rafizadeh C; Zink RW; Yumibe NP; Ajamie RT; Wilken B; Devanarayan V
Bioorg Med Chem Lett; 2006 Dec; 16(24):6293-7. PubMed ID: 17005393
[TBL] [Abstract][Full Text] [Related]
40. Novel 2,7-Substituted (S)-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acids: Peroxisome Proliferator-Activated Receptor γ Partial Agonists with Protein-Tyrosine Phosphatase 1B Inhibition.
Otake K; Azukizawa S; Takeda S; Fukui M; Kawahara A; Kitao T; Shirahase H
Chem Pharm Bull (Tokyo); 2015; 63(12):998-1014. PubMed ID: 26633022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
